Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
about
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemiaAn update of current treatments for adult acute myeloid leukemiaClass III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisMolecular Genetic Markers in Acute Myeloid Leukemia'Acute myeloid leukemia: a comprehensive review and 2016 update'Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.Molecular therapy for acute myeloid leukaemia.The Future of Targeting FLT3 Activation in AML.Identification of an orally available compound with potent and broad FLT3 inhibition activityFLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AMLRevealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupPretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaStem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.How I treat FLT3-mutated AML.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.Midostaurin for the treatment of acute myeloid leukemia.Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemiaImpact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.Molecular landscape in acute myeloid leukemia: where do we stand in 2016Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.Acute myeloid leukaemia genomics.Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.Emerging therapies for acute myeloid leukemia: translating biology into the clinic.Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyMidostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
P2860
Q26771438-5EDED6DE-0C45-46BB-B452-31B05F0B3227Q26776396-C849EFB6-FDEB-4BFB-A69A-4F04469170BDQ26797245-1DC1FC20-A871-4CEB-8D31-06607D23037CQ26799606-D8EC1C9C-47D8-4E16-9259-A56D7CA210BFQ28072539-DCFCB7DB-9361-4230-A662-53204458C51BQ28646898-E6FF686C-28E1-4D41-B5DE-0D0362E44A49Q33774504-EF24601F-5D4D-4DEB-A954-70CA82FCBD02Q33925672-B0BC1A43-DD18-4F5B-9AA0-41AB74A34EFAQ34555386-3FB40709-59DE-46EB-A5EC-8918233A7631Q35789739-D20FA1D2-E660-43B4-A328-58EB5C916D5AQ36484100-8E077492-40F3-48D6-9B99-592616A0E8A5Q36544560-28678F93-5107-4DD1-AFBE-C6F36BEE1ED1Q36805474-87EA33EE-6697-49F5-A9D5-4CEFDCA93B11Q37270982-05D2D275-5283-4165-A843-D10D9D124C1FQ37316816-CE98DABF-11F4-4C92-877D-6C1EDDAF547BQ37623389-D4AE3D8B-E42A-49CA-A1D8-46338BCB9945Q37624593-3269D13D-549D-40E8-AE4C-7A29BE986D0AQ37638749-EF7656CB-6FED-47A2-8C46-EEB1E6563657Q38568355-5193722B-ADEA-4050-B2AF-E326DC0D5324Q38671401-57E9A833-ECA0-4658-B988-9737C90E2038Q38848054-F2149A76-0707-4444-8B0F-A1119644C8C1Q38863489-1748FA5F-43D5-4068-9967-8125253FCAFEQ38892684-681BC1D0-CBFD-4008-9D18-2E9BE85ECD84Q39040937-3CAF7509-27DA-45A6-9603-82E88EE0F5D8Q39116878-B1024A44-DD1E-46B0-A75E-EE2E50239C4AQ39252132-C31BC6D4-74EF-4C29-875C-A8A5BBB482A1Q39400164-65BC292E-DD5F-4E03-81E4-09C5F38AA4FBQ39601810-EF2ACE80-8E79-4097-874D-82C8D2A18A8DQ39674948-28711317-3CD0-4B8B-AADE-32BD06B5D349Q40396505-523B8FF8-77BC-4FCB-8E1C-29E3945EDE11Q40513646-491C6E7F-C05F-4395-881F-1C1F3FB59161Q40832501-22F0C7BE-E03A-4A36-874D-4AD3475FBA3DQ41509184-9A5D8BF9-F458-4A0B-BB19-66BFB49142DAQ41984963-6E847077-BCE5-40BE-B7F5-7BFB81EB0577Q42365051-E4FF4B80-986E-4DAA-B69F-CF0BA3E9CBFFQ42376734-9ED39447-9888-4D55-911D-8D6D7435BE44Q42391575-5EF04418-4F7D-4B3A-A355-ACF2D79A861DQ47439297-9AB54140-7C04-40F2-A7DE-F95C9DED7D3BQ47727992-9E4C4BD8-595A-45A6-A43A-AF5A5F1B62F1Q47877035-FC8465CC-2728-48EA-AAE7-9A41DC5C914C
P2860
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Differential impact of allelic ...... to allogeneic transplantation.
@en
type
label
Differential impact of allelic ...... to allogeneic transplantation.
@en
prefLabel
Differential impact of allelic ...... to allogeneic transplantation.
@en
P2093
P1433
P1476
Differential impact of allelic ...... to allogeneic transplantation.
@en
P2093
Alexander Lamparter
Arnold Ganser
Axel Benner
Daniela Späth
David Nachbaur
Gerald Wulf
Gerhard Held
German-Austrian AML Study Group
Guido Kobbe
Heinz A Horst
P304
P356
10.1182/BLOOD-2014-05-578070
P407
P577
2014-09-30T00:00:00Z